Novo Nordisk's Buyback Ledger, a Pediatric Insulin Label and CagriSema Subgroup Data All Wait on 4 November

Novo Nordisk has kept its share repurchase programme running, disclosing cumulative buybacks worth DKK 11,187,348,102 since 4 February. The mandatory filing with the US Securities and Exchange Commission, which tracks the programme through Friday, puts the company's holding of its own stock at 1.2% of share capital.

That is a sizeable return of capital, and investors should read it as exactly that — nothing more. Buybacks say nothing about whether Novo is winning the fight for patients, nor about how the business is trading. Keeping the capital-return story separate from the commercial and legal ones matters, because the two are pulling in different directions.

A courtroom rebuff, narrowly framed

On the legal front, a US judge has rejected Novo's request for a preliminary injunction against Eli Lilly's advertising for weight-loss medicines, according to Reuters. Novo's suit over allegedly misleading promotion continues, and the court did not rule on whether the ads were in fact deceptive.

The upshot is limited: Novo cannot immediately halt the contested campaigns, but the underlying claim remains live. Nor does the ruling by itself tell investors anything concrete about shifting market share.

A pediatric label for the weekly insulin

Against that setback sits a genuine product advance. The FDA has approved Awiqli, a once-weekly basal insulin, for children aged ten and older with type-2 diabetes. According to the company, the label cuts basal insulin injections from seven a week to one.

CagriSema, Novo's next-generation weight-loss candidate, adds a further data point — though one that needs careful handling. Two post-hoc analyses of the Phase 3 REDEFINE 1 trial, published on 20 October, reported an average weight loss of 25.0% among 2,309 women, against 3.0% on placebo, measured at 68 weeks.

The critical qualifier is that these figures rest on a treatment-adherence assumption, and they come from retrospective analyses of an existing study rather than a fresh trial. A second cut of the data split the cohort by menopausal status: 26.7% average weight loss for women before menopause, 24.8% during it and 23.1% after. The breakdown sharpens the picture of the groups studied, but it does not lift the adherence caveat, and the subgroup numbers alone do not explain the differences between them.

Nor should the 25.0% headline be confused with the full trial result, where weight loss came in at 22.7% — short of Novo's own 25% target.

The date that matters

All of these threads — the buyback tally, the injunction denial, the pediatric approval and the CagriSema readouts — address different questions, and none of them settles the one investors are really asking about. That answer is due on 4 November, when Novo publishes results for the first nine months of 2026.

Until then the picture stays split down the middle: capital flowing back to shareholders, a pipeline notch on the board, additional efficacy data in a defined subgroup, and a courtroom dispute still awaiting a ruling on the merits.